Pfizer, Moderna and COVID-19

Moderna COVID Vaccine Technology Struck Down by PTAB
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed.
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation,
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Fierce Pharma3h
Pfizer, BioNTech notch US win—and loss in Germany—amid high-stakes patent fight with Moderna
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Why You Shouldn’t Be Buying MRNA Stock At $35
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Moderna (MRNA) Stock Climbs as CEO and Director Make Strategic Insider Purchases
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism
The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.
Moderna aims 2027 approval for Merck-partnered cancer shot
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
Here's Why Moderna Stock Soared 16% on Wednesday
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.